Estrella Immunopharma, Inc. (ESLA) intrinsic value & 10-year financials
Estrella Immunopharma, Inc. (ESLA) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.43
- Market cap
- $15.8M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- 180.9%
- Free cash flow (FY2025)
- —
ESLA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$13.1M | -$0.35 | — | — | 428.8% |
| FY2024 | — | -$7.3M | -$0.27 | — | — | 195.7% |
| FY2023 | — | -$11.1M | -$0.41 | — | — | 158.8% |
| FY2022 | — | -$996.1K | — | — | — | 96.2% |
| FY2021 | — | -$247.7K | — | — | — | 24.8% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Estrella Immunopharma, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Estrella Immunopharma, Inc. has earned high returns on invested capital, averaging 25.8% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
Over the decade, Estrella Immunopharma, Inc. shows that management has aggressively returned capital to shareholders by retiring 64.9% of outstanding shares.
Benjamin Graham lens
Estrella Immunopharma, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.